Palvella Therapeutics Inc... (PVLA)
NASDAQ: PVLA
· Real-Time Price · USD
65.78
3.15 (5.03%)
At close: Oct 03, 2025, 3:59 PM
65.91
0.20%
After-hours: Oct 03, 2025, 07:44 PM EDT
5.03% (1D)
| Bid | 56.8 |
| Market Cap | 727.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.13M |
| EPS (ttm) | -2.55 |
| PE Ratio (ttm) | -25.8 |
| Forward PE | -18.64 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 70 |
| Volume | 150,602 |
| Avg. Volume (20D) | 160,155 |
| Open | 62.75 |
| Previous Close | 62.63 |
| Day's Range | 61.73 - 65.78 |
| 52-Week Range | 11.17 - 65.78 |
| Beta | -0.13 |
| Ex-Dividend Date | n/a |
About PVLA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PVLA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PVLA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
-15.72%
Palvella Therapeutics shares are trading lower on ...
Unlock content with
Pro Subscription
8 months ago
+6.26%
Palvella Therapeutics shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a price target of $44.
1 month ago · https://thefly.com
Palvella Therapeutics price target raised to $66 from $52 at CanaccordCanaccord raised the firm's price target on Palvella Therapeutics to $66 from $52 and keeps a Buy rating on the shares. The firm said its 2Q25 earnings report was incremental following enrollment comp...
2 months ago · https://thefly.com
Palvella Therapeutics initiated with an Outperform at Raymond JamesRaymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...